PHARMACOKINETICS, SAFETY AND TOLERABILITY OF THE HCV NS5A INHIBITOR ABT-267 FOLLOWING SINGLE AND MULTIPLE DOSES IN HEALTHY ADULT VOLUNTEERS

被引：14
|
作者：
Dumas, E. O. [1 ]
Lawal, A. [1 ]
Menon, R. M. [1 ]
Podsadecki, T. [1 ]
Awni, W. [1 ]
Dutta, S. [1 ]
Williams, L. [1 ]
机构：
[1] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
JOURNAL OF HEPATOLOGY | 2011年 / 54卷
关键词：
D O I：
10.1016/S0168-8278(11)61206-3
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1204
引用
收藏
页码：S475 / S476
页数：2
相关论文
共 50 条
  • [21] Safety, Tolerability and Pharmacokinetics of Yimitasvir Phosphate Capsule, a Novel Oral Hepatitis C Virus NS5A Inhibitor, in Healthy Chinese Volunteers
    Nan Zhao
    Ran Xie
    Xia Zhao
    Hong Zhao
    Bo Jia
    Yingjun Zhang
    Lin Luo
    Zhangma Huang
    Jing Li
    Xingan Wang
    Huan Yan
    Bixia He
    Hongming Xie
    Qingyun Ren
    Yimin Cui
    Clinical Drug Investigation, 2019, 39 : 671 - 681
  • [22] Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of Vixotrigine in Healthy Volunteers
    Naik, Himanshu
    Steiner, Deb J.
    Versavel, Mark
    Palmer, Joanne
    Fong, Regan
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2021, 14 (04): : 1272 - 1279
  • [23] SAFETY, AND TOLERABILITY OF NIM811, A NOVEL CYCLOPHILIN INHIBITOR FOR HCV, FOLLOWING SINGLE AND MULTIPLE ASCENDING DOSES IN HEALTHY VOLUNTEERS AND HCV-INFECTED PATIENTS
    Ke, J.
    Lawitz, E.
    Rozier, R.
    Marbury, T.
    Nguyen, N.
    Serra, D.
    Dole, K.
    Praestgaard, J.
    Huang, M.
    Evans, T.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S229 - S229
  • [24] Pharmacokinetics, Safety, and Tolerability Evaluation of Single and Multiple Doses of GSK3342830 in Healthy Volunteers
    Tenero, David
    Farinola, Nicholas
    Berkowitz, Elchonon M.
    Tiffany, Courtney A.
    Qian, Yanwen
    Xue, Zhengyu
    Raychaudhuri, Aparna
    Gardiner, David F.
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2019, 8 (06): : 754 - 764
  • [25] Pharmacokinetics, Safety and Tolerability of EDP-239, a Novel Hepatitis C (HCV) NS5A inhibitor, in Patients with HCV Infection
    Jiang, Lijuan
    Jiang, Xuemin
    Dole, Kiran
    Lawitz, Eric
    Poordad, Fred
    Zeuzem, Stefan
    Caliri, Kimberley
    Tack, Kenneth
    Colvin, Richard
    Or, Yat Sun
    HEPATOLOGY, 2015, 62 : 1307A - 1308A
  • [26] Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of Youkenafil Hydrochloride, a Phosphodiesterase Type 5 Inhibitor, in Healthy Chinese Male Volunteers
    Liang, Beibei
    Wang, Jin
    Bai, Nan
    Chi, Yulong
    Wang, Rui
    Cai, Yun
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2022, 11 (10): : 1184 - 1190
  • [27] Pharmacokinetics and pharmacodynamics of single and multiple oral doses of a novel 5-lipoxygenase inhibitor (ABT-761) in healthy volunteers
    Wong, SL
    Drajesk, J
    Chang, M
    Lanni, C
    Witt, G
    Hansen, R
    Awni, WM
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (03) : 324 - 331
  • [28] Safety and pharmacokinetics of dicloxacillin in healthy Chinese volunteers following single and multiple oral doses
    Wu, Guolan
    Zheng, Yunliang
    Zhou, Huili
    Hu, Xingjiang
    Liu, Jian
    Zhai, You
    Zhu, Meixiang
    Wu, Lihua
    Shentu, Jianzhong
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 5687 - 5695
  • [29] Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers
    Butler, Kathleen
    Teng, Renli
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 70 (01) : 65 - 77
  • [30] A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of V-7404 in Healthy Adult Volunteers
    Kankam, Martin K.
    Burns, Jennifer M.
    Collett, Marc S.
    Corrado, Michael L.
    Hincks, Jeffrey R.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2021, 65 (10)
12345